A Novel Dual HDAC6 and Tubulin Inhibitor, MPT0B451, Displays Anti-tumor Ability in Human Cancer Cells in Vitro and in Vivo

The combination cancer therapy is a new strategy to circumvent drug resistance for the treatment of high metastasis and advanced malignancies. Herein, we developed a synthesized compound MPT0B451 that display inhibitory effect against histone deacetylase (HDAC) 6 and tubulin assembly. Our data demon...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Pharmacol
Auteurs principaux: Wu, Yi-Wen, Hsu, Kai-Cheng, Lee, Hsueh-Yun, Huang, Tsui-Chin, Lin, Tony E., Chen, Yi-Ling, Sung, Ting-Yi, Liou, Jing-Ping, Hwang-Verslues, Wendy W., Pan, Shiow-Lin, HuangFu, Wei-Chun
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2018
Sujets:
Pharmacology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5859083/
https://ncbi.nlm.nih.gov/pubmed/29593536
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2018.00205
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires